The Effect of Clinical Parameters on Muscle Oxygenation in Patients with COPD

Bandırma Onyedi Eylül University

Status: Completed

Conditions: Muscle Oxygenation; Respiratory Function; Chronic Obstructive Pulmonary Disease; Disease Severity

Study type: Observational

Funder types: Other

Identifiers

NCT06041126

2023-72

Details and patient eligibility

About

The aim of this study is to examine the peripheral muscle oxygenation of patients with Chronic Obstructive Pulmonary Disease at rest, during submaximal exercise and recovery, and to examine the effects of disease severity and respiratory functions on peripheral muscle oxygenations. In this study, the effect of disease severity and respiratory problems on peripheral muscle metabolism of patients with COPD will be explained.

Enrollment: 41 patients

Sex: All

Ages: 40 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Being diagnosed with COPD (according to GOLD Staging: GOLD 1, GOLD 2, GOLD 3, GOLD 4)
• Being between the ages of 40-80
• Body Mass Index <35
• Not having an acute exacerbation in the last 3 months

Exclusion criteria

• Patients who do not want to participate in the study
• Arthritis causing weakness in the lower extremity, neurological disease, deep vein thrombosis, peripheral arterial disease, muscle weakness, fracture etc. patients with the condition
• Common diseases such as malignancy, pulmonary embolism, vasculitis, collagen tissue diseases, interstitial fibrosis, severe pneumonia patients with parenchymal destruction
• Patients with severe dyspnea and hemodynamic instability who cannot perform the 6 Minute Walk Test

Trial design

41 participants in 2 patient groups

Group one

Description:

Patients with COPD according to the combined COPD assessment Global Intervention (GOLD) guidelines, participants who are in groups A and B (mild-moderate) will be included in group 1.

Group two

Description:

COPD patients according to the combined COPD assessment, according to the "Global Intervention (GOLD) guidelines", participants who are in groups C and D (severe-very severe) will be included in group 2.